Articles
8 June 2009
Vol. 2 No. 3: Cervo Preclinical Working Conference, Cervo Ligure, October 6-8, 2005
https://doi.org/10.4081/hmr.v2i3.370

Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
173
Views
236
Downloads

Authors

M Coscia
support@pagepress.org
E Quaglino
C Curcio
F Pantaleoni
G Forni
M Massaia
Zoledronic acids (Zol) is the most potent aminobisphosphonate clinically available.1 Preclinical in vivo data suggest that it modulates the development of bone disease, decreases tumor burden2 with a direct anti-cancer activity,3-5 and reduces the migration and the metastatic invasion of cancer cells.6

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.370